|Bid||336.52 x 1300|
|Ask||336.98 x 900|
|Day's Range||334.92 - 342.25|
|52 Week Range||226.02 - 342.25|
|Beta (3Y Monthly)||1.11|
|PE Ratio (TTM)||84.72|
|Earnings Date||Aug 1, 2019|
|Forward Dividend & Yield||1.36 (0.40%)|
|1y Target Est||341.27|
WAYNE, Pa., July 18, 2019 -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the second quarter 2019 will be released before market open on.
Abbott (ABT) registers strong Cardiovascular and Neuromodulation sales on double-digit growth in Electrophysiology, Heart Failure and Structural Heart.
Chemed's (CHE) VITAS shows higher adoption via an expanded average daily census. Also, the Roto-Rooter's business grows on the back of strong core plumbing and drain cleaning service segments.
The launch of this system is in sync with NuVasive's (NUVA) endeavor to deliver end-to-end solutions that offer predictable clinical and economic outcomes in spine surgery.
Boston Scientific (BSX) is currently pinning hopes on a stronger performance in China, backed by the recent approval of SYNERGY in the country.
Positive outcomes prove to be a major breakthrough for Medtronic (MDT) in the growing field of ventricular assist devices.
4D surgical techniques for insertion of UroLift System implants and a single-centre study showing significant cost savings with the use of the UroLift System treatment compared with traditional surgery. Teleflex Incorporated (TFX) today thanked its United Kingdom-based Physician Advocates for their Poster Presentations highlighting the UroLift® System, as well as real world proof of its cost effectiveness, at this year’s BAUS meeting which finished on June 26th. The first Presentation, by Dr. Mark Rochester*, Consultant Urologist from Norfolk and Norwich University Hospital, shared promising, early results of the UroLift System treatment of BPH patients with acute urinary retention.
ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.
Integra LifeSciences (IART) expects its partnership with Tissue Analytics to be perfectly strategic as the latter's software solutions automatically derive high quality data from clinical pictures.
The identification of a group of peptides and proteins is a remarkable step toward Phibro's (PAHC) development of a solution for ASF.
WAYNE, Pa., July 09, 2019 -- Teleflex Incorporated (NYSE: TFX) today announced the publication of positive results from a multi-center study reaffirming the safety and.
The sale of oncology bead products by Boston Scientific (BSX) is expected to be among the last steps undertaken by the company to obtain Federal Trade Commission's approval for BTG buyout.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...